Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of rocatinlimab in moderate-to-severe atopic dermatitis
NCT03096223Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Apr 2017
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rocatinlimab in atopic dermatitis (AD), sponsored by Kyowa Kirin. Primary endpoint: Incidence of treatment-emergent adverse events or drug-related TEAEs at 22 weeks. Started Apr 2017; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03096223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096223.